Payment overview · 2025
General Payments
$238.89
4 reported records · 1 companies
Healthcare provider profile · identity verified
Thomas Daniel Mihelich, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TULSA, OK · NPI 1538193214
Verified facts
What the public records show
CMS Open Payments records show Thomas Daniel Mihelich, MD received $238.89 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $238.89 | 100.0% | 4 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $238.89 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 373 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 226 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 57 |
| Losartan Potassium | Losartan Potassium | 206 | 59 |
| Spironolactone | Spironolactone | 203 | 57 |
| Ozempic | Semaglutide | 201 | 24 |
| Simvastatin | Simvastatin | 201 | 56 |
| Lisinopril | Lisinopril | 189 | 48 |
| Atenolol | Atenolol | 169 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 42 |
| Metformin Hcl Er | Metformin Hcl | 148 | 43 |
| Eliquis | Apixaban | 147 | 28 |
| Trazodone Hcl | Trazodone Hcl | 130 | 28 |
| Allopurinol | Allopurinol | 120 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 29 |
| Potassium Chloride | Potassium Chloride | 116 | 34 |
| Metformin Hcl | Metformin Hcl | 104 | 30 |
| Alendronate Sodium | Alendronate Sodium | 99 | 21 |
| Gabapentin | Gabapentin | 92 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 22 |
| Omeprazole | Omeprazole | 78 | 23 |
| Furosemide | Furosemide | 77 | 19 |
| Meloxicam | Meloxicam | 76 | 23 |
| Lovastatin | Lovastatin | 71 | 19 |
| Mounjaro | Tirzepatide | 68 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 17 |
| Montelukast Sodium | Montelukast Sodium | 67 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 13 |
| Celecoxib | Celecoxib | 49 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 13 |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Carvedilol | Carvedilol | 43 | 13 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 14 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Klor-Con M10 | Potassium Chloride | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Eplerenone | Eplerenone | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $238.89 · 4 records | ABBVIE INC. | — | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error